These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 25678490)

  • 1. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with
    Garin E; Rolland Y; Pracht M; Le Sourd S; Laffont S; Mesbah H; Haumont LA; Lenoir L; Rohou T; Brun V; Edeline J
    Liver Int; 2017 Jan; 37(1):101-110. PubMed ID: 27514012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.
    Garin E; Lenoir L; Edeline J; Laffont S; Mesbah H; Porée P; Sulpice L; Boudjema K; Mesbah M; Guillygomarc'h A; Quehen E; Pracht M; Raoul JL; Clement B; Rolland Y; Boucher E
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1057-68. PubMed ID: 23613103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
    Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
    J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Garin E; Rolland Y; Edeline J
    Semin Nucl Med; 2019 May; 49(3):218-226. PubMed ID: 30954188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.
    Chiesa C; Mira M; Maccauro M; Spreafico C; Romito R; Morosi C; Camerini T; Carrara M; Pellizzari S; Negri A; Aliberti G; Sposito C; Bhoori S; Facciorusso A; Civelli E; Lanocita R; Padovano B; Migliorisi M; De Nile MC; Seregni E; Marchianò A; Crippa F; Mazzaferro V
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
    Lam MG; Goris ML; Iagaru AH; Mittra ES; Louie JD; Sze DY
    J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.
    Garin E; Rolland Y; Laffont S; Edeline J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):559-75. PubMed ID: 26338177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
    Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
    J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
    Kulik LM; Carr BI; Mulcahy MF; Lewandowski RJ; Atassi B; Ryu RK; Sato KT; Benson A; Nemcek AA; Gates VL; Abecassis M; Omary RA; Salem R
    Hepatology; 2008 Jan; 47(1):71-81. PubMed ID: 18027884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraarterial Hepatic SPECT/CT Imaging Using 99mTc-Macroaggregated Albumin in Preparation for Radioembolization.
    Gates VL; Singh N; Lewandowski RJ; Spies S; Salem R
    J Nucl Med; 2015 Aug; 56(8):1157-62. PubMed ID: 26089551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma.
    Palard X; Edeline J; Rolland Y; Le Sourd S; Pracht M; Laffont S; Lenoir L; Boudjema K; Ugen T; Brun V; Mesbah H; Haumont LA; Loyer P; Garin E
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):392-401. PubMed ID: 29177870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization with
    Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
    Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.